← All trials
NCT04979221
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 26, 2021
- Primary completion
- Jan 26, 2022
- Completion date
- Feb 28, 2022
- First posted
- Jul 28, 2021
- Last posted
- Aug 3, 2021
- Enrollment
- 274
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Federal University of Health Science of Porto AlegreLead sponsor
- Federal University of Health Science of Porto AlegreReponsible party - principal investigator
- Federal University of Health Science of Porto AlegreOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.